ئەز   Haval Mohammed Salih

ackground: Hepatitis C virus (HCV) is a public health issue. Successful treatment of HCV infection results in sustained virologic response (SVR) in the majority of subjects. Subsequent recurrence of HCV, either from late relapse or reinfection, may occur. The aim of this study was to assess the recurrence rate of HCV in Iraqi patients. Methods: In this study, 113 patients who completed anti-HCV therapy successfully were recruited. While 23 patients received a classical regimen of peg-interferon plus ribavirin, 90 patients received direct-acting antiviral therapy. Those patients were followed up for three years. HCV recurrence rate was calculated using events/person years of follow-up (PYFU). Results: Among the recruited patients, HCV RT-PCR was positive in 1 (0.88%) patient giving a recurrence rate of 2.95 per 1000 PYFU. When the data were stratified according to the treatment regimen, the recurrence rate was 14.49 per 1000 PYFU in patients who received the classical regimen of interferon and ribavirin. Conclusions: The overall recurrence rate was low in Iraq. No recurrence was recorded in patients received direct-acting antiviral therapy. Further studies are needed with a larger sample size and longer follow-up to determine the relapse rate in Iraq.

Cutaneous leishmaniasis (CL) is endemic in Iraq. After the last war in Iraq against Islamic State in Iraq and Syria (ISIS), the number of CL cases has peaked particularly in children. International guidelines do not provide an insight on how to choose treatment regimen of CL in children. The aim of this article was to study the efficacy of intralesional sodium stibogluconate (SSG) therapy for school age children with CL. In the period between June 2016 and June 2019, 288 internally displaced school age children (6-12 years old) from Ninewa city were recruited in the study. All patients received intralesional SSG twice a week for a maximum of 12 sessions. All patients were followed up for 12 weeks after the last treatment session. The mean age of recruited patients was 8.6 ± 2 years and 164/288 (56.9%) were male. 202/288 (70.1%) of the patients presented with single lesion. The total number of lesions was 417 of which 141/417 (33.8%) lesion were nodular and the rest were ulcerative lesions. The treatment success rate was (282/288) 97.91%. No significant association was found between age, gender, number of lesions, or duration of lesions and the treatment outcome. Mild local pain, mild bleeding at the site of injection, and itching at the site of injection were the most common side effects. Intralesional SSG infiltrate is effective and minimal side effects. Further studies including clinical trials are required to provide robust data on the efficacy and the safety.

Cutaneous Leishmaniasis (CL) is caused by protozoan parasites called Leishmania. CL is endemic in Iraq and caused by L. tropica and L. major species. 1 Antimonial medications are the most commonly prescribed treatments for the infection. Other drugs, such as itraconazole and paromomycin, have been used with varying success. A Cochrane study, 2 analyzing the different regimens for the treatment of CL, concluded that they were difficult to evaluate due to the variability of the regimens used, the inconsistency of the duration of the studies, the diversity of clinical conditions and the difference of Leishmania species. 2 Besides, critical methodology-related issues, study design quality, and reporting weakness of these clinical trials were present in the reports published. Such issues made comparing the results and meta-analyzing the data difficult, and no conclusions could be drawn. 3 CL may lead to a …